Results 181 to 190 of about 831,586 (304)

Long‐term efficacy and safety of romiplostim plus immunosuppressive therapy as first‐line treatment in patients with aplastic anaemia: 2‐year interim analysis of observational study of two clinical trials

British Journal of Haematology, EarlyView.
Jong Wook Lee, Kohei Hosokawa, Jun Ho Jang, Naoshi Obara, Masashi Sawa, Kensuke Usuki, Gaku Oshikawa, Masahiro Kizaki, Koji Nagafuji, Ting‐An Lin, Hitoshi Hanamoto, Yeung‐Chul Mun, Toshiro Kawakita, Kazunori Imada, June‐Won Cheong, Sung‐Soo Park, Takayuki Tabayashi, Masaru Gamou, Kenta Murotani, Hirohito Yamazaki   +19 more
wiley   +1 more source

Impact of Hemoglobin Improvement on Survival in Patients With Myelofibrosis and Anemia Treated With Momelotinib in the SIMPLIFY‐1 and MOMENTUM Trials

European Journal of Haematology, EarlyView.
In this post hoc analysis of the phase 3 SIMPLIFY‐1 and MOMENTUM trials, the number of patients with baseline hemoglobin < 10 g/dL who achieved hemoglobin ≥ 10 g/dL by week 24 with momelotinib, as well as the time to achievement, were evaluated. Patients who were JAK inhibitor naive and/or had moderate anemia were more likely and faster to achieve this
Francesca Palandri, Casey O'Connell, Pankit Vachhani, Donal P. McLornan, Steffen Koschmieder, Juan Carlos Hernandez‐Boluda, Kazuya Shimoda, Shiyuan Zhang, Catherine Ellis, Jessica Lim, Jasmine Sahni, Vikas Gupta   +11 more
wiley   +1 more source

Optimizing platelet transfusion thresholds in preterm infants: a systematic review and narrative synthesis of impacts on survival and neurodevelopment. [PDF]

Blood Transfus
Liu D, Gao Q, Kumar J, Yue Y, Shi J, Tang J, Xiong T.   +6 more
europepmc   +1 more source

Project Sickle Cure: A Prospective, International Observational Study of Hematopoietic Cell Transplantation for Sickle Cell Disease

European Journal of Haematology, EarlyView.
ABSTRACT Background Sickle cell disease (SCD) is a chronic and life‐limiting hemoglobin and systemic vascular disease. While over 1000 people have undergone hematopoietic cell transplantation (HCT) over the last 40 years, long‐term disease‐specific and health‐related quality of life data are lacking.
Gregory M. T. Guilcher, Allistair Abraham, Staci D. Arnold, Christine Camacho‐Bydume, Jenny Duong, Scott Gillespie, Ann Haight, Monica L. Hulbert, Naresh Kumar, Katie Liu, Cherry Mammen, Aleksandra Mineyko, Abra Morgan, Alexander Ngwube, Robert S. Nickel, Araby Roberts, Fiona Schulte, Stephen Sands, Akshay Sharma, John T. Horan, Elizabeth O. Stenger   +20 more
wiley   +1 more source

Risks Make Routine Plasma and Platelet Transfusion Recommendations Concerning in Certain Critical Care Populations. [PDF]

Chest
Adkins BD, Yates SG, Sarode R.
europepmc   +1 more source

The Effect of Polycythemia Vera on Pregnancy Complications. The Analysis of an American Population Database With Over 9 Million Deliveries

European Journal of Haematology, EarlyView.
ABSTRACT Objectives Polycythemia Vera (PV) is characterized by overproduction of erythrocytes, leading to a hypercoagulable state. Evidence regarding associations between PV and pregnancy outcomes is limited. The aim of our study was to provide robust evidence regarding the prevalence of pregnancy complications in women with PV.
Noah Margolese, Sarah Al‐Rayes, Shaonie Ton‐Leclerc, Ahmad Badeghiesh, Haitham Baghlaf, Michael H. Dahan   +5 more
wiley   +1 more source

Platelet transfusion induces transfusion-associated circulatory overload in rats with myocardial infarction. [PDF]

Transfusion
Phelp PG, Hurks B, Polet CA, Roelofs JJTH, Tuip-de Boer AM, Kapur R, Vlaar APJ, van den Brom CE, Klanderman RB.   +8 more
europepmc   +1 more source

Feasibility and Safety of Venetoclax for Cytoreduction During Induction Therapy in Newly Diagnosed Acute Promyelocytic Leukemia

European Journal of Haematology, EarlyView.
ABSTRACT Objective This study aimed to evaluate the feasibility and safety of venetoclax as a cytoreductive strategy during induction therapy in newly diagnosed acute promyelocytic leukemia (APL), and to provide an exploratory description of its early efficacy.
Yu Wang, Rong Xiao, Xiaobing Huang, Yi Xiao   +3 more
wiley   +1 more source

Optimizing platelet transfusion thresholds based on TEG maximum clot strength (MA value) to reduce platelet usage and improve patient outcomes in liver transplantation: a cohort study. [PDF]

Front Med (Lausanne)
Qi P, Wu C, Zhou J, Tang R.
europepmc   +1 more source

Dose‐Adjusted Treatment With 7‐Day Venetoclax Plus Azacitidine or Decitabine in Patients With Acute Myeloid Leukaemia

European Journal of Haematology, EarlyView.
ABSTRACT Acute myeloid leukaemia (AML) in older or unfit patients is commonly treated with hypomethylating agents (HMA) plus venetoclax (VEN), but prolonged VEN exposure often causes substantial haematological toxicity. We retrospectively analysed 61 elderly AML patients treated with HMA + VEN for 7 (7d), 14 (14d) or > 14 days (> 14d) per cycle.
Laurenz Steiner, Lina S. Silva‐Bermudez, Mahmoud Ghazal, Mohammed Abba, Catharina Gerhards, Georgia Metzgeroth, Alice Fabarius, Stefan Klein, Sebastian Kreil, Nanni Schmitt, Patrick Wuchter, Wolf‐Karsten Hofmann, Alexander Streuer   +12 more
wiley   +1 more source